Histological profile and age at diagnosis of breast and ovarian tumors: A register-based study in Espirito Santo, Brazil

ELDAMÁRIA DE VARGAS WOLFGRAMM1, CAMILA FÁTIMA BIANCARDI GAVIOLI1, MAYARA LEMOS ENTRINGER1, LYVIA NEVES REBELLO ALVES1, ELAINE STUR1, ALLAN KARDEC DE CASTRO NETO2, LUCIENE LAGE DA MOTTA3, FAUSTO EDMUNDO LIMA PEREIRA1 and IURI DRUMOND LOURO1

1Center of Molecular and Human Genetics, Department of Biology, Federal University of Espirito Santo, Vitória 29043-900; 2Pathology Laboratory, Santa Rita de Cássia Hospital, Vitória 29043-260; 3Pathology Laboratory, Santa Casa de Misericórdia de Vitória Hospital, Vitória 29018-180, Espirito Santo, Brazil

Received September 18, 2012; Accepted October 29, 2012

DOI: 10.3892/mco.2012.38

Abstract. Breast and ovarian cancers are important public health problems in Brazil. However, in various locations in the Brazilian territory these types of cancer remain poorly characterized. Therefore, this study aimed to compare data collected from the Pathology Services of two Oncology Reference Hospitals in Espirito Santo state (Brazil) with the data in previous Brazilian studies. Histological type frequency and age at diagnosis of breast and ovarian tumors between 2001-2004 and 2009-2010 were analyzed. Tumor size, histological grade, lymph node status, hormone receptor status [estrogen (ER) and progesterone receptors (PR)] as well as HER2 and Ki-67 marker status were obtained for the cases of infiltrating ductal carcinomas of the breast during the period 2009-2010. Categorical variables were described by their absolute and/or relative frequencies, while quantitative variables were expressed as the mean ± standard deviation and median, using 95% confidence intervals. Chi-square tests were performed to examine whether or not the studied variables differed by age at the time of diagnosis. Malignant breast tumors (1,758) and 119 malignant ovarian tumors were examined. Mean ages for malignant breast and ovarian tumors were 53.59 and 52.98 years, respectively. An increased tumor frequency in the age group of ≤35 years was observed for other malignant tumors of the breast during the period of 2009-2010, compared to 2001-2004. When considering only infiltrating ductal carcinomas with immunohistochemistry records available, there were 82.1% (133 cases) of ER+/PR+ tumors, 1.9% (3 cases) of ER+/PR-/HER2 tumors, 1.64% (26 cases) of ER+/PR+/HER2 tumors. The findings of this study demonstrated detailed information concerning breast and ovarian tumor behavior in the Espirito Santo state (Brazil), allowing for a precise comparison with other populations (Brazilian or international), which may be helpful in the planning of prevention and treatment strategies.

Introduction

Breast cancer is the most common malignant tumor among women, accounting for one in four types of cancer diagnosed in women worldwide. Over 1.1 million women are diagnosed with this disease each year and incidence rates are still on the increase in several countries (1). In Brazil, breast cancer is an important public health problem, due to the high incidence, morbidity and mortality rates (1), which are unequally distributed throughout the country, with the South and Southeast constituting the regions with the highest reported breast cancer rates (2).

An incidence ratio of 52 breast cancer cases per 100,000 women is estimated in Brazil for 2012 (52,680 cases/year). The Southeast region has the highest incidence ratio of 69 new cases/100,000 women, while the South region has a similar incidence ratio of 65 cases/100,000 women (3). The Espirito Santo state, located in the Southeast region, has a breast cancer rate of 49.42/100,000 women for the year 2012, while the State’s capital, Vitória, a rate of 71.28/100,000 women (3). Recently, the Brazilian media reported significant increases in breast cancer incidence in women <35 years of age, generating public distress and concern (4).

Ovarian cancer is the fourth most frequent type of cancer in women. According to American studies, the risk ratio of developing ovarian cancer in a woman’s life-time is estimated to be 1/70. The incidence increases with age, reaching its peak in the eighth decade (5).

During the period 2001-2005, the age-adjusted mortality rate due to ovarian cancer was 8.8/100,000 women per year in the United States (6). In Europe, various mortality rates
have been reported. In Germany and the majority of western European countries, ovarian cancer incidence is almost 12/100,000 women, while it is lower in Southern Europe (9.3/100,000 women in Italy) and France (9.7/100,000 women). Total mortality due to ovarian cancer in Poland is 12.5/100,000 women, while the highest rate is reported in Northern Europe (13.9/100,000 women in Norway and 13.4/100,000 women in the UK) (7).

Ovarian cancer is also a public health problem in Brazil. Although not the most common type of female cancer, it constitutes a major cause of mortality among gynecological cancers (8). According to the estimations 5,530 Brazilian women were diagnosed with ovarian cancer in 2008, with 2,982 women succumbing to the disease (3.0/100,000 women) (9).

According to data obtained from the Brazilian National Cancer Institute (Instituto Nacional de Câncer, INCA), an incidence ratio of 6.17 cases per 100,000 women is estimated in Brazil for 2012 (6,190 cases/year). The Southeast region has demonstrated an estimated risk of 7 new cases per 100,000 women and the Espirito Santo state has demonstrated a previously reported rate of 5.92/100,000 women (3).

In an attempt to provide current data and a more comprehensive analysis of Brazilian breast and ovarian cancer epidemiology, this study aimed to examine histological type frequencies and age at the time of diagnosis for breast and ovarian tumors in Espirito Santo state, Brazil. Moreover, tumor size, histological grade, lymph node and hormone receptor status [estrogen (ER) and progesterone receptors (PR)] as well as HER2 and Ki-67 marker status for infiltrating ductal carcinomas, the most frequent malignant tumor of the breast, were investigated. Information was obtained after reviewing data from the Pathology Services of two Oncology Reference Hospitals in Espirito Santo state [the Santa Rita de Cássia and the Santa Casa de Misericórdia de Vitória Hospitals (Vitoria, Brazil)].

Materials and methods

Data collection and categorization. Female breast and ovarian, malignant and benign tumor data accumulated during the period 2001-2004 in the Pathology Service of the Santa Casa de Misericórdia de Vitória Hospital as well as for 2001-2004 and 2009-2010 in the Pathology Service of the Santa Rita de Cássia Hospital were analyzed. Information concerning histological type and age at the time of diagnosis were obtained for the breast and ovarian tumors. Tumor size, histological grade, lymph node and hormone receptor status (ER/PR) as well as HER2 and Ki-67 marker status were obtained for infiltrating ductal carcinomas of the breast during 2009-2010 in the Santa Rita de Cássia Hospital.

Breast tumors were categorized into infiltrating ductal carcinomas, carcinomas, other malignant tumors, fibroadenomas and other benign tumors. Ovarian tumors were categorized into serous cystadenocarcinomas, mucinous cystadenocarcinomas, carcinomas, other malignant tumors, serous cystadenomas, mucinous cystadenomas, teratomas and other benign tumors. Immunohistochemical analysis of ER, PR and HER2 gene products was used to categorize tumors as luminal (ER+/PR+), HER2 (ER+/PR+/HER2 +) and triple-negative (ER/PR/HER2 -).

Patients that sought medical assistance at the studied Hospitals are representative of the entire population of Espirito Santo state with regard to breast and ovarian cancer, since the two hospitals are Cancer Reference Hospitals for the residents of the surrounding urban and rural regions.

Statistical analysis. The SPSS version 17.0 and GraphPad Prism 5 were used for data handling and statistical analyses. For the descriptive analysis, categorical variables were described by their absolute and/or relative frequencies, and quantitative variables were expressed as the mean ± standard deviation (SD) and median, using 95% confidence intervals (CI). Chi-square tests were performed to examine whether or not the studied variables differed among the age groups ≤35, ≥36 to ≤ 55 and ≥56 years. This study was approved by the Ethics Committee of the Federal University of Espirito Santo (Vitoria, Brazil; protocol no. 02/09), including the informed consent waiver, and was performed in compliance with the Ethical Standards of the Declaration of Helsinki in 1975.

Results

Distribution of breast tumors by histological type and their correlation to age. There were 1,758 malignant, 2,570 benign and 21 phyllodes tumors of the breast during the period analyzed. Infiltrating ductal carcinoma was the most frequent malignant tumor (81.74%), responsible for 33.04% (1,437 cases) of the breast tumor cases (Table I).

The mean age at diagnosis for malignant breast tumors was 53.59 years (SD, 13.29; 95% CI, 52.96-54.21), with a median age of 52 years (range 14-101), respectively, accounting for 15.1% of the cases (266 cases; 95% CI, 13.43-16.77) <40 and 2.1% of the cases (37 cases; 95% CI, 1.43-2.77) ≥50 years. When considering only cases ≤35 years (126 cases), a mean age of 31.38 (SD, 3.66; 95% CI, 30.83-32.12) and a median age of 32 years were observed, accounting for 70.63% of the cases (89 cases; 95% CI, 62.68-78.58) ≥30 years. The distribution of breast tumors by histological type and their correlation to age are described in Table I.

Frequency of breast tumors. Breast tumor frequency in the age groups ≤35, 36-55 and ≥56 years is shown in Fig. 1. A statistically significant higher frequency of infiltrating ductal carcinomas was observed in the 36-55 (P<0.0001) and ≥56 year (P<0.0001) age groups during 2009-2010, compared to 2001-2004 (Fig. 1B and C). Additionally, a higher frequency was observed for other malignant tumors in the age groups analyzed (P=0.0172, P=0.0011 and P<0.0001 for the groups ≤35, 36-55 and ≥56 years, respectively) (Fig. 1A-C). No additional significant frequency differences were observed for carcinomas of the breast in the age groups during the time periods analyzed.

Fibroadenomas developed less frequently in the age groups ≤35 and 36-55 years (P<0.0001 for both groups) during 2009-2010, when compared to 2001-2004 (Fig. 1A and B). Similarly, other benign tumors of the breast developed less frequently in the age group ≤35 years (P<0.0001) during 2009-2010 compared to 2001-2004 (Fig. 1A).

Frequency and histological characteristics of infiltrating ductal carcinomas. The histological characteristics of the
infiltrating ductal carcinomas registered in the Santa Rita de Cássia Hospital during 2009-2010 are described in Table II. Undifferentiated tumors (grade III) comprised 9.4% (10 cases) in the age group ≤35 years, 49.1% (52 cases) in the age group 36-55 years and 41.5% (44 cases) in the age group ≥56 years.

With regard to hormone receptors, 38.9% (21 cases) were ER+\(^+\), 6.7% (9 cases) were ER-\(^-\), 37% (20 cases) were PR+\(^+\) and 18.5% (10 cases) were PR-\(^-\) in the age group ≤40 years, while 38.7% (86 cases) were ER+\(^+\), 11.3% (25 cases) were ER-\(^-\), 33.8% (75 cases) were PR+\(^+\) and 15.3% (34 cases) were PR-\(^-\) in the age group ≥50 years. For the age group ≤35 years, 2.60% (5 cases) were ER-/PR-\(^-\) and 4.69% (9 cases) were ER+/PR+\(^+\).

Regarding HER2 expression, 80% (8 cases) of the HER2 3+ cases (overexpression cases) were diagnosed in the age group 36-55 years. Concerning the Ki-67 marker, ~50% (93 cases) of the positive cases were diagnosed in the age group 36-55 years.

We observed 82.1% (133 cases) of luminal tumors, 1.9% (3 cases) of HER2 tumors and 16.04% (26 cases) of triple-negative tumors. A statistically significant trend towards triple-negative tumors was observed in the age group ≤35 years (P=0.0360).

Concerning ovarian tumors, mucinous cystadenocarcinomas had the highest mean age at diagnosis (60 years; SD, 8.426), while teratomas the lowest (37.02 years; SD, 14.969) (Table I). A higher frequency was observed for other malignant tumors of the ovary and serous cystadenomas in the age group ≥56 years (P=0.0151 and P=0.0255, respectively) during the period 2009-2010 compared to 2001-2004 (Fig. 1F).

**Discussion**

This study investigated the histological type frequency and the age at the time of diagnosis of breast and ovarian tumors in the Espirito Santo state, Brazil. Samples were obtained from two Oncology Reference Hospitals. Breast and ovarian cancer histological types were similar for the two Hospitals. However, the Santa Rita de Cássia Hospital had a significantly larger number of cancer cases, justifying the collection of data for 2009-2010 only from this Hospital.

Data regarding tumor size, histological grade, lymph node status and hormone receptor status as well as HER2 and Ki-67 marker status for infiltrating ductal carcinomas
were available only for the time period 2009-2010, due to the lack of information for previous years and for other types of malignant tumors.

The mean age at diagnosis for malignant breast tumors in our study was similar to that of another study analyzing samples from Florianópolis (Santa Catarina, Brazil) (10). By contrast, our results demonstrated a lower mean and median age at diagnosis when compared with cases from Juiz de Fora (Minas Gerais, Brazil) (11). The age group of ≤35 years also presented results similar those of the study conducted with samples obtained from Florianópolis (12). Frequencies observed in the age groups ≤30 and ≤40 years were different from the frequencies described in the literature, reporting ~0.6% of cancer cases in women <30 years and 6.5% in women <40 years (13).

The fact that the cancer rates were higher during 2009-2010 when compared to 2001-2004 was consistent with a Brazilian study conducted examining samples from Goiânia (Goiás, Brazil) (4). According to this study (4), a significant increase in breast cancer incidence was observed in the age groups (20-39, 40-59 and ≥60 years) over the years analyzed (1988-2003). This increase in breast cancer rates may be due to an improvement in cancer screening programs resulting from a wider clinical application of mammography.

Figure 1. Frequency of breast and ovarian tumors registered in the Pathology Services. (A and D) Age group ≤35 years, (B and E) age group 36-55 years, (C and F) age group ≥56 years. (A-C) Breast tumors, (D-F) ovarian tumors. DC, infiltrating ductal carcinoma; CA, other carcinomas; OM, other malignancies; FD, fibroadenoma; OB, other benign tumors; SCC, serous cystadenocarcinoma; MCC, mucinous cystadenocarcinoma; SCN, serous cystadenoma; MCN, mucinous cystadenoma; TE, teratoma.
Table II. Histological characteristics of infiltrating ductal carcinomas during 2009-2010.

<table>
<thead>
<tr>
<th>Histological characteristics</th>
<th>n (% , 95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histological grade I</td>
<td>14 (4.4, 2.1-6.7)</td>
</tr>
<tr>
<td>II</td>
<td>197 (62.1, 56.8-67.4)</td>
</tr>
<tr>
<td>III</td>
<td>106 (33.4, 28.2-38.6)</td>
</tr>
<tr>
<td>Tumor size, right breast T1</td>
<td>37 (72.5, 60.2-84.8)</td>
</tr>
<tr>
<td>T2</td>
<td>12 (23.5, 11.9-35.1)</td>
</tr>
<tr>
<td>T3</td>
<td>2 (3.9, 0.0-9.2)</td>
</tr>
<tr>
<td>Tumor size, left breast T1</td>
<td>40 (65.6, 53.7-77.5)</td>
</tr>
<tr>
<td>T2</td>
<td>17 (27.9, 16.6-39.2)</td>
</tr>
<tr>
<td>T3</td>
<td>4 (6.6, 0.4-12.8)</td>
</tr>
<tr>
<td>Tumor size, without location</td>
<td>154</td>
</tr>
<tr>
<td>T1</td>
<td>107 (69.5, 62.2-76.8)</td>
</tr>
<tr>
<td>T2</td>
<td>42 (27.3, 20.3-34.3)</td>
</tr>
<tr>
<td>T3</td>
<td>5 (3.2, 0.4-5.9)</td>
</tr>
<tr>
<td>Lymph node status Positive</td>
<td>104 (27.4, 22.9-31.9)</td>
</tr>
<tr>
<td>Negative</td>
<td>275 (72.6, 68.1-77.1)</td>
</tr>
<tr>
<td>ER status Positive</td>
<td>152 (77.9, 72.1-83.7)</td>
</tr>
<tr>
<td>Negative</td>
<td>43 (22.1, 16.3-27.9)</td>
</tr>
<tr>
<td>PR status Positive</td>
<td>139 (72.4, 66.1-76.7)</td>
</tr>
<tr>
<td>Negative</td>
<td>53 (27.6, 21.3-33.9)</td>
</tr>
<tr>
<td>HER2 status 1+</td>
<td>14 (40, 23.8-56.2)</td>
</tr>
<tr>
<td>2+</td>
<td>11 (31.4, 16.0-46.8)</td>
</tr>
<tr>
<td>3+</td>
<td>10 (28.6, 13.6-43.6)</td>
</tr>
<tr>
<td>Ki-67 status Positive</td>
<td>186 (99.5, 98.5-100.5)</td>
</tr>
<tr>
<td>Negative</td>
<td>1 (0.5, 0.0-1.5)</td>
</tr>
</tbody>
</table>

CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor.

Infiltrating ductal carcinomas demonstrated no statistically significant differences in histological grade, lymph node involvement and tumor size in the age groups. These results are consistent with a study using samples from Ribeirão Preto (São Paulo, Brazil) (13), where no differences in histopathological tumor features were observed in the age groups ≤40, 40-50 and ≥50 years at diagnosis. By contrast, a study analyzing samples of invasive ductal breast cancer in Belém (Pará, Brazil) (14) provided different results. That study reported 59.1% T4 tumors (26 cases), 93.2% of locally advanced disease at diagnosis (41 cases; T3 and T4 tumors) and 93.2% of clinically affected lymph nodes (41 cases) (14), while the present study observed 4.14% T3 tumors (11 cases; 95% CI, 1.75-6.53) and 27.4% lymph node-positive tumors (104 cases; 95% CI, 22.91-31.89). The higher rates observed in the study conducted using samples from Belém (14) are likely to be due to the fact that the patients had advanced disease at diagnosis, as they were undergoing pre-surgical neoadjuvant chemotherapy. However, the samples analyzed in the present study accounted for all the tumor patients admitted to the Santa Rita de Cassia Hospital Pathology Service.

In contrast to other Brazilian studies, no statistically significant differences were observed in hormone receptor expression in the analyzed age groups. Studies using samples from Ribeirão Preto (13) demonstrated that PR+ tumors were less frequent in women aged ≤40 years compared to women aged ≥50 years (36.2% or 21 cases vs. 58.4% or 38 cases), while studies using samples from Florianópolis (12) found 38.9% (35 cases) ER/PR+ and 24.5% (22 cases) ER+/PR+ tumors in the age group ≤35 years.

HER2 overexpression in the present study was similar to other studies in the literature, where HER2 was overexpressed in ~15-25% of the breast cancers (14). When comparing patients aged ≥50 years to those aged ≤50 years, no statistically significant differences were observed in the HER2 expression. Similar results were observed in samples from Ribeirão Preto (13). The luminal immunohistochemical profile observed in our study (82.1%; 95% CI, 76.20-88.0%) was higher compared to results of other studies available in the literature (60-70%) (15), as well as compared to the Brazilian sample reported by Bacchi et al (15), reporting a luminal profile percentage of 68.2% (249 cases). By contrast, although consistent with our results, in their study Bacchi et al (15) also observed a trend towards triple-negative profile in the younger age group (27.1%, 79 cases).

The mean age at diagnosis observed for malignant ovarian tumors in the present study was consistent with that of a Brazilian study using samples from São Paulo (São Paulo) (16) which reported a mean age at diagnosis of 53.5 years, accounting for 58.8% of the patients ≥50 years of age. The mean age for malignant ovarian tumors was also in concordance with the findings of a study using samples from Jundiaí (São Paulo, Brazil) (17), reporting a mean age of 55 years at diagnosis for malignant ovarian tumors.

In their study, DeLand et al (18) reported a mean age at diagnosis for malignant ovarian tumors (50 years) that was similar to the findings of the present study, although the mean age for benign tumors (34 years) was lower compared to the one we detected.

Breast and ovarian tumors are poorly characterized epistemologically in several Brazilian regions, thus this study adds considerably to other Brazilian studies, providing detailed information about the Espírito Santo state. Improved knowledge on these tumors may have direct implications on the prevention, diagnosis and treatment strategies in Brazil and other countries.

Acknowledgements

This study was funded in part by Fibria Celulose. EVW was supported by a FAPES PhD scholarship. CFBG, MLE, LNRA, and ES were supported by a CNPq scholarship.
References


